Please login to the form below

Not currently logged in
Email:
Password:

Millennium expands Velcade tests

Millennium Pharmaceuticals begins tests to evaluate its blood cancer drug Velcade in combination with other drugs

Millennium Pharmaceuticals has begun tests to evaluate its blood cancer drug Velcade (bortezomib) in combination with other drugs.

Velcade, which Millennium is developing with Johnson & Johnson Pharmaceutical Research and Development (J&JPRD), can be prescribed to patients with multiple myeloma who have received at least one prior therapy.

The phase II trial will evaluate the efficacy of combining Velcade for injection with lenalidomide, dexamethasone and cyclophosphamide in the front-line multiple myeloma setting.

In a press statement, Millennium's CMO Nancy Simonian, said: "The objective of this trial is to evolve the treatment of multiple myeloma by combining these highly active therapies to induce early complete remission and improve long term survival."

16th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics